SUMMARY
Desmopressin
Acetate
Injection
Amiodarone hydrochloride injection is a class III antiarrhythmic drug.
Amiodarone HCl injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Amiodarone injection also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with intravenous amiodarone injection patients may be transferred to oral amiodarone therapy (see DOSAGE AND ADMINISTRATION).
Amiodarone injection should be used for acute treatment until the patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but amiodarone injection may be safely administered for longer periods if necessary.
|
NEWS HIGHLIGHTS
Published Studies Related to Amiodarone Injection (Amiodarone)
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. [2009.09.15]
OBJECTIVES: We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF). BACKGROUND: Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm. Few data are available to directly compare the efficacy and safety of dronedarone versus amiodarone... CONCLUSIONS: Dronedarone is less effective than amiodarone for the maintenance of sinus rhythm, but has fewer adverse effects. For every 1,000 patients treated with dronedarone instead of amiodarone, we estimate approximately 228 more recurrences of AF in exchange for 9.6 fewer deaths and 62 fewer adverse events requiring discontinuation of drug.
A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. [2009.09]
BACKGROUND: Atrial fibrillation (AF) occurs commonly after anatomic pulmonary resection. In this study, the efficacy of amiodarone for prevention of post-pulmonary resection AF was investigated... CONCLUSIONS: Amiodarone prophylaxis significantly reduces the incidence of AF after anatomic pulmonary resection, and is associated with a significant reduction in length of intensive care unit stay.
Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. [2009.07]
OBJECTIVES: To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization... CONCLUSIONS: As compared with digoxin and amiodarone, intravenous diltiazem was safe and effective in achieving VR control to improve symptoms and to reduce hospital stay in patients with acute AF.
Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. [2009.04]
Intravenous amiodarone is an effective agent for the treatment of recurrent ventricular fibrillation and hemodynamically unstable ventricular tachycardia. PM101 is a new formulation of intravenous amiodarone that uses a cyclodextrin to maintain amiodarone in the aqueous phase... No safety concerns unique to PM101 were identified.
Prevention of atrial fibrillation after coronary artery bypass grafting via atrial electromechanical interval and use of amiodarone prophylaxis. [2009.04]
In our previous study, we defined a cut-off point of 120 ms for atrial electromechanical interval (AEMi) to determine the risk of atrial fibrillation (AF) occurrence. Accordingly, the present study sought to investigate whether or not a prophylactic perioperative administration of amiodarone could reduce the incidence of AF in a high-risk group (AEMi >120 ms) undergoing coronary artery bypass grafting (CABG)...
Clinical Trials Related to Amiodarone Injection (Amiodarone)
Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft [Completed]
Concentrations of Amiodarone in Fat Tissue During Chronic Treatment [Completed]
The objective of this study is to determine if concentrations of amiodarone in fat tissue
increase constantly over time during chronic treatment with this drug, and if blood
concentrations reflect accurately the concentrations in fat tissue or not. This is because
excessive concentrations of this drug in tissues can produce adverse effects.
Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation [Completed]
Our hypothesis is that episodic amiodarone treatment (i. e. amiodarone treatment 1 month prior
until 1 month after cardioversion) is associated with a lower morbidity and a higher quality
of life compared to continuous prophylactic amiodarone treatment while atrial fibrillation is
still effectively suppressed. The latter means that at the end of the study permanent atrial
fibrillation is prevented in comparable percentage of patients (70%) in both treatment
strategies. However, this will be accomplished at the cost of a higher number of electrical
cardioversions (2-3) in the episodic treatment group compared to the continuous treatment
group.
Amiodarone to Prevent Post-Operative Arrhythmias [Completed]
Rapid heart rhythms originating from the upper heart chambers (atrial tachyarrhythmias) are
very common after open-heart surgery. The hypothesis of the PAPABEAR study is that a brief
(13 day) peri-operative course of oral amiodarone therapy would be effective and safe for the
prevention of these post-operative atrial tachyarrhythmias.
Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation [Active, not recruiting]
The objective of this study is to compare the efficacy and safety of dronedarone to that of
amiodarone for the treatment of patients with atrial fibrillation.
|
